Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Accumulated Expenses: 2021-2024

Historic Other Accumulated Expenses for Relay Therapeutics (RLAY) over the last 4 years, with Dec 2024 value amounting to $2.0 million.

  • Relay Therapeutics' Other Accumulated Expenses fell 20.50% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 20.50%. This contributed to the annual value of $2.0 million for FY2024, which is 65.28% up from last year.
  • Latest data reveals that Relay Therapeutics reported Other Accumulated Expenses of $2.0 million as of FY2024, which was up 65.28% from $1.2 million recorded in FY2023.
  • Relay Therapeutics' Other Accumulated Expenses' 5-year high stood at $26.2 million during FY2022, with a 5-year trough of $396,000 in FY2021.
  • For the 3-year period, Relay Therapeutics' Other Accumulated Expenses averaged around $9.8 million, with its median value being $2.0 million (2024).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 6,504.04% in 2022, then crashed by 95.40% in 2023.
  • Over the past 4 years, Relay Therapeutics' Other Accumulated Expenses (Yearly) stood at $396,000 in 2021, then surged by 6,504.04% to $26.2 million in 2022, then crashed by 95.40% to $1.2 million in 2023, then surged by 65.28% to $2.0 million in 2024.